Clinical Trials on Nasal Bleeding in Portugal

Total 82 results

Hospital Pedro Hispano

Unknown

Efficacy of PuraStat for the Prevention of Delayed Bleeding After Endoscopic Resection of Colorectal Lesions

Bleeding After Resection of Colorectal Neoplastic Lesions

Portugal
Centro Hospitalar de Vila Nova de Gaia/Espinho,...

Recruiting

Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield (PrepRICE)

Obscure Gastrointestinal Bleeding

Portugal
Hospital da Senhora da Oliveira
Medtronic

Completed

Pan-intestinal Capsule Endoscopy Versus Colonoscopy in Iron Deficiency Anemia or Overt GI Bleeding

Iron Deficiency Anemia | GastroIntestinal Bleeding

Portugal
Universidade do Porto

Unknown

Sclerotherapy With Polidocanol Foam In The Treatment Of Hemorrhoidal Disease In Patients With Bleeding Disorders

Hemorrhoids | Bleeding Disorder

Portugal
University of Lisbon
Fundação para a Ciência e a Tecnologia; Faculdade de Psicologia, Universidade... and other collaborators

Recruiting

The SmartFeeding4Kids: Study of a New Web-based Food Parenting Intervention (SF4K)

Parental Feeding Practices and Children's Healthy Diet

Portugal
University of Coimbra
Joana Marta-Simões

Completed

#KindGirlsInACTion: A Programme for the Promotion of Mental Health of Female Adolescents (KindGirlsACT)

Quality of Life | Body Image | Emotion Regulation | Eating Disorders | Eating Behavior | Psychological | Relations, Interpersonal

Portugal
Campus Neurológico Sénior

Completed

Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease

Parkinson Disease

Portugal
Centro Hospitalar de Lisboa Central
Sociedade Portuguesa de Neonatologia

Unknown

Effect of Target Fortified Human Milk on the Growth Quality of Very Preterm Infants (TargetFort) (TargetFort)

Growth | Body Composition | Adiposity | Prematurity | Feeding Patterns | Nutrient Deficiency | Breast Milk Collection

Portugal
Instituto Politécnico de Leiria

Completed

Upper Limb Reeducation Across Life Span (ULReed)

Cerebral Palsy | Dementia | Upper Extremity Dysfunction | Cognitive Decline | Eating Disorders

Portugal
Centro Hospitalar de Lisboa Central

Not yet recruiting

Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.

Parkinson Disease | Botulinum Toxin | Freezing of Gate

Portugal
Campus Neurológico Sénior
Johns Hopkins University

Completed

The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients

Parkinson Disease

Portugal
Campus Neurológico Sénior
University of Lisbon

Completed

Feasibility of the AHA Exergame System in Parkinson's Disease Patients

Parkinson Disease

Portugal
Albino Maia
Centro Hospitalar Lisboa Ocidental; Centro Hospitalar De São João, E.P.E.; Centro... and other collaborators

Recruiting

Deep Brain Stimulation-Induced Mania in Parkinson's Disease (BPD_DBS)

Parkinson Disease | Mania

Portugal
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Parkinson's Disease

Portugal, Romania, Ukraine
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

Parkinson's Disease (PD)

Portugal
AstraZeneca

Completed

European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) (ENERGIB)

Gastrointestinal Hemorrhage | Non-variceal Upper Gastrointestinal Bleeding | Gastrointestinal Ulcer

Italy, Spain, Turkey, Norway, Belgium, Portugal, Greece
Novo Nordisk A/S

Completed

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Belgium, Germany, France, United Kingdom, Italy, Hungary, Austria, Sweden, Iran, Islamic Republic of, Argentina, Ireland, Poland, Portugal, Slovakia
NeuraLight
European Clinical Research Infrastructure Network

Recruiting

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease (PALOMA)

Parkinson Disease

United States, Switzerland, Portugal, United Kingdom, Spain
Juvantia Pharma Ltd
Santhera Pharmaceuticals

Unknown

Fipamezole in Neurogenic Orthostatic Hypotension (Foehn)

Parkinson's Disease | Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension (NOH)

France, Portugal
Novo Nordisk A/S

Completed

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Saudi Arabia, Algeria, Turkey, Germany, Poland, Netherlands, Italy, Belgium, South Africa, United Kingdom, Sweden, Austria, Portugal, France, Czech Republic, Venezuela
Sanofi

Completed

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Obesity | Eating Disorders

United States, France, Netherlands, Portugal, Sweden, Switzerland, Finland
Centre National de la Recherche Scientifique, France
Instituto de Medicina Molecular João Lobo Antunes

Unknown

Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison (FraLusoPark)

Disease Progression | Parkinson's Disease | Dysarthria | Speech | Medical Treatment | Cross-language

France, Portugal
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
University College, London
Lund University; University Hospital, Bordeaux; Ludwig-Maximilians - University... and other collaborators

Completed

Care for Late Stage Parkinsonism (CLaSP)

Parkinson's Disease | Late Stage Parkinson's Disease

Netherlands, United Kingdom, Germany, France, Portugal, Sweden
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Hoffmann-La Roche

Completed

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Basal Cell Carcinoma

Italy, Czechia, Hungary, Belgium, Canada, Ireland, Mexico, Portugal, Slovenia, Spain, Turkey, Brazil, Bosnia and Herzegovina, Romania, United Kingdom, Germany, Israel, France, Greece, Russian Federation, Lithuania, Netherlands, Norway, Colomb... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Belgium, Mexico, Turkey, Israel, Spain, Sweden, Argentina, Canada, Japan, United States, Australia, Chile, Portugal, Russian Federation
Sanofi

Completed

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Parkinson Disease

France, Canada, Germany, Netherlands, Portugal, Spain, Sweden, Tunisia, Denmark, Morocco, South Africa, Austria, United Kingdom
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in CRSsNP (Liberty CRSsNP)

Chronic Sinusitis | Sinusitis | Chronic Rhinosinusitis Without Nasal Polyps | Sinus Disorder | Respiratory Disorder

Belgium, Spain, Argentina, Ukraine, Portugal, China, United States, Canada, Chile, Hungary, Korea, Republic of, Russian Federation, Sweden

Clinical Trials on Nasal Bleeding in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations